Swiss National Bank Decreases Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Swiss National Bank lessened its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 67,600 shares of the medical research company's stock after selling 3,400 shares during the period. Swiss National Bank owned about 0.23% of Bio-Rad Laboratories worth $21,827,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BIO. ING Groep NV acquired a new stake in Bio-Rad Laboratories during the 3rd quarter worth about $44,000. GAMMA Investing LLC bought a new stake in Bio-Rad Laboratories in the fourth quarter worth approximately $42,000. Bfsg LLC acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at approximately $77,000. Signaturefd LLC lifted its stake in Bio-Rad Laboratories by 15.8% in the fourth quarter. Signaturefd LLC now owns 352 shares of the medical research company's stock valued at $114,000 after buying an additional 48 shares during the period. Finally, Banque Cantonale Vaudoise boosted its holdings in shares of Bio-Rad Laboratories by 25.0% during the 3rd quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company's stock worth $135,000 after buying an additional 75 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Up 3.4 %

Shares of BIO traded up $9.05 on Thursday, reaching $277.31. The company's stock had a trading volume of 200,651 shares, compared to its average volume of 206,637. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $431.79. The stock has a market capitalization of $7.91 billion, a PE ratio of -12.48 and a beta of 0.94. The company has a current ratio of 5.83, a quick ratio of 4.34 and a debt-to-equity ratio of 0.14. The firm has a fifty day moving average of $315.16 and a 200-day moving average of $313.94.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The medical research company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.04 by $0.25. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The firm had revenue of $610.82 million during the quarter, compared to the consensus estimate of $619.09 million. During the same period in the prior year, the business posted $3.34 earnings per share. The company's quarterly revenue was down 9.8% compared to the same quarter last year. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BIO shares. Royal Bank of Canada dropped their target price on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating on the stock in a research report on Friday, February 16th. UBS Group cut their price objective on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating on the stock in a research report on Wednesday. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, April 25th. Finally, Citigroup lowered Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and cut their price target for the stock from $400.00 to $365.00 in a report on Wednesday, April 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $461.00.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the transaction, the executive vice president now owns 6,942 shares of the company's stock, valued at approximately $2,332,512. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 17.50% of the company's stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.